Affinity Asset Advisors, LLC 13F holdings, Q1 2025
Holdings as of March 31, 2025 · filings on SEC EDGAR · latest filing →
Affinity Asset Advisors, LLC disclosed 81 US equity positions worth $638.8m in its Q1 2025 13F filing. The largest position was XENE at 7.0% of the reported book, followed by APGE and VRNA. Against the Q4 2024 filing, it opened 8 new positions, added to 23 and reduced 13 among the top 50 holdings.
What did Affinity Asset Advisors, LLC own in Q1 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2024 |
|---|---|---|---|---|---|---|---|
| 1 | XENE XENON PHARMACEUTICALS INC | Healthcare | 7.0% | $44.6m | 1,328,175 | 14% | added |
| 2 | APGE APOGEE THERAPEUTICS INC | Healthcare | 6.7% | $43.0m | 1,151,199 | 24% | added |
| 3 | VRNA VERONA PHARMA PLC | 6.1% | $39.0m | 615,000 | -7% | reduced | |
| 4 | ACLXGBX ARCELLX INC | 5.4% | $34.8m | 530,000 | 25% | added | |
| 5 | ALKS ALKERMES PLC | Healthcare | 5.2% | $33.0m | 1,000,000 | -9% | reduced |
| 6 | NUVALENT INC | 5.1% | $32.6m | 460,000 | 61% | added | |
| 7 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 4.1% | $26.5m | 80,000 | -3% | reduced |
| 8 | CNTA CENTESSA PHARMACEUTICALS PLC | 3.5% | $22.2m | 1,546,662 | 41% | added | |
| 9 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 3.4% | $21.5m | 1,400,000 | 0% | held |
| 10 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 3.0% | $19.3m | 400,000 | 208% | added |
| 11 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 3.0% | $19.2m | 1,070,000 | 435% | added |
| 12 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 2.7% | $17.5m | 1,100,000 | 214% | added |
| 13 | SPY SPDR S&P 500 ETF TR | 2.6% | $16.8m | 30,000 | – | new | |
| 14 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 2.3% | $14.7m | 1,825,000 | 22% | added |
| 15 | OMEROS CORP | 2.2% | $14.3m | 15,525,000 | 0% | held | |
| 16 | MERUS N V | 2.1% | $13.6m | 321,962 | -17% | reduced | |
| 17 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.8% | $11.7m | 100,000 | 33% | added |
| 18 | KARYOPHARM THERAPEUTICS INC | 1.8% | $11.6m | 15,250,000 | 0% | held | |
| 19 | ESTA ESTABLISHMENT LABS HLDGS INC | Healthcare | 1.8% | $11.4m | 280,000 | 0% | held |
| 20 | INSM INSMED INC | Healthcare | 1.7% | $10.7m | 140,000 | 180% | added |
| 21 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 1.6% | $10.4m | 300,000 | 50% | added |
| 22 | NRIX NURIX THERAPEUTICS INC | Healthcare | 1.5% | $9.6m | 810,669 | -14% | reduced |
| 23 | VERA VERA THERAPEUTICS INC | Healthcare | 1.3% | $8.5m | 355,143 | -16% | reduced |
| 24 | TRVI TREVI THERAPEUTICS INC | Healthcare | 1.2% | $7.9m | 1,250,000 | – | new |
| 25 | SYRE SPYRE THERAPEUTICS INC | 1.2% | $7.8m | 481,678 | -42% | reduced | |
| 26 | IMVT IMMUNOVANT INC | Healthcare | 1.2% | $7.3m | 430,000 | 330% | added |
| 27 | TVTX TRAVERE THERAPEUTICS INC | 1.1% | $7.0m | 7,000,000 | 17% | added | |
| 28 | NEWAMSTERDAM PHARMA COMPANY | 1.0% | $6.7m | 325,000 | -24% | reduced | |
| 29 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 0.9% | $5.6m | 545,362 | 48% | added |
| 30 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 0.9% | $5.5m | 50,000 | – | new |
| 31 | AVTX AVALO THERAPEUTICS INC | Healthcare | 0.8% | $5.3m | 657,154 | 19% | added |
| 32 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 0.8% | $5.3m | 390,000 | 144% | added |
| 33 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 0.8% | $5.1m | 1,480,881 | – | new |
| 34 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 0.8% | $5.1m | 152,252 | -67% | reduced | |
| 35 | RZLT REZOLUTE INC | 0.8% | $4.9m | 1,700,000 | 8% | added | |
| 36 | CATX PERSPECTIVE THERAPEUTICS INC | 0.7% | $4.7m | 2,224,196 | 71% | added | |
| 37 | AUTL AUTOLUS THERAPEUTICS PLC | Healthcare | 0.7% | $4.7m | 3,045,000 | -32% | reduced |
| 38 | ERAS ERASCA INC | Healthcare | 0.7% | $4.6m | 3,341,519 | 34% | added |
| 39 | PROQR THRAPEUTICS N V | 0.7% | $4.4m | 3,284,512 | 16% | added | |
| 40 | QURE UNIQURE NV | 0.7% | $4.2m | 400,000 | – | new | |
| 41 | PERCEPTIVE CAP SOLUTIONS COR | 0.6% | $3.6m | 350,000 | 0% | held | |
| 42 | SLNOEUR SOLENO THERAPEUTICS INC | 0.6% | $3.6m | 50,000 | -62% | reduced | |
| 43 | INOZYME PHARMA INC | 0.6% | $3.5m | 3,867,710 | -3% | reduced | |
| 44 | AKBA AKEBIA THERAPEUTICS INC | Healthcare | 0.5% | $2.9m | 1,500,000 | – | new |
| 45 | MAZE MAZE THERAPEUTICS INC | 0.4% | $2.8m | 250,000 | – | new | |
| 46 | NEWAMSTERDAM PHARMA COMPANY | 0.4% | $2.7m | 241,957 | 2% | added | |
| 47 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 0.4% | $2.7m | 100,000 | 150% | added |
| 48 | OAKTREE ACQUISITION CORP III | 0.4% | $2.6m | 250,000 | 0% | held | |
| 49 | GERN GERON CORP | Healthcare | 0.4% | $2.4m | 1,500,000 | -33% | reduced |
| 50 | MNPR MONOPAR THERAPEUTICS INC | 0.4% | $2.3m | 62,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.